AT1R blockade reduces IFN-γ production in lymphocytes in vivo and in vitro

Kidney International

Volumn 67, Issue 6, 2005, Pages 2134-2142

  Weidanz, Jon A ^b   Jacobson, Lynn M ^b   Muehrer, Rebecca J ^b   Djamali, Arjang ^b   Hullett, Debra A ^b   Sprague, Jenifer ^b   Chiriva Internati, Maurizio ^b   Wittman, Vaughan ^b   Thekkumkara, Thomas J ^b   Becker, Bryan N ^a  

^a UW Nephrology   (United States)

^b NONE

Author keywords

Angiotensin II, kidney transplantation, angiotensin receptor blockers, chronic allograft nephropathy, lymphocyte proliferation; Cytotoxic T lympocyte line; Peripheral blood lymphocytes, IFN

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CALCINEURIN INHIBITOR; CANDESARTAN; GAMMA INTERFERON; LOSARTAN; RAPAMYCIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; MESSENGER RNA; TETRAZOLE DERIVATIVE;

ADULT; ALLOIMMUNITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO CULTURE; LYMPHOCYTE; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; AGED; BIOSYNTHESIS; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION;

ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; FEMALE; HUMANS; INTERFERON TYPE II; LOSARTAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLES;

EID: 23044500474     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00318.x     Document Type: Article

References (19)

1. KUNERT-RADEK J, STEPIEN H, KOMOROWSKI J, PAWLIKOWSKI M: Stimulatory effect of angiotensin II on the proliferation of mouse spleen lymphocytes in vitro is mediated via both types of angiotensin II receptors. Biochem Biophys Res Commun 198:1034-1039, 1994
2. NAHMOD KA, VERMEULEN ME, RAIDEN S, et al: Control of dendritic cell differentiation by angiotensin II. FASEB J 17:491-493, 2003
3. DORFFEL Y, LATSCH C, STUHLMULLER B, et al: Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34:113-117, 1999
4. NAPOLEONE E, DI SANTO A, CAMERA M, et al: Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 86:139-143, 2000
5. CHEN X, WANG J, ZHOU F, et al: STAT proteins mediate angiotensin II-induced production of TIMP-1 in human proximal tubular epithelial cells. Kidney Int 64:459-467, 2003
6. LIANG H, VENEMA VJ, WANG X, et al: Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. J Biol Chem 274:19846-19851, 1999
7. SHAO J, NANGAKU M, MIYATA T, et al: Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42:31-38, 2003
8. NANKIVELL BJ, GRUENEWALD SM, ALLEN RD, CHAPMAN JR: Predicting glomerular filtration rate after kidney transplantation. Transplantation 59:1683-1689, 1995
9. MACKENZIE DA, SOLLINGER HW, HULLETT DA: Role of CD4+ regulatory T cells in hyperbaric oxygen-mediated immune nonresponsiveness. Hum Immunol 61:1320-1331, 2000
10. GEBAUER BS, HRICIK DE, ATALLAH A, et al: Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2:857-866, 2002
11. BECKER BN, JACOBSON LM, BECKER YT, et al: Renin-angiotensin system gene expression in post-transplant hypertension predicts allograft function. Transplantation 69:1485-1491, 2000
12. HOFFMANN TK, LOFTUS DJ, NAKANO K, et al: The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53 (264-272) epitope. J Immunol 168:1338-1347, 2002
13. SUZUKI Y, GOMEZ-GUERRERO C, SHIRATO I, et al: Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of renin-angiotensin system: The role of NF-AT pathway. J Immunol 169:4136-4146, 2002
14. NATARAJ C, OLIVERIO MI, MANNON RB, et al: Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104:1693-1701, 1999
15. FERNANDEZ-CASTELO S, ARZT ES, PESCE A, et al: Angiotensin II regulates interferon-gamma production. J Interferon Res 7:261-268, 1987
16. UNGER T: Significance of angiotensin type 1 receptor blockade: Why are angiotensin II receptor blockers different? Am J Cardiol 84:9S-15S, 1999
17. COOK JL, ZHANG Z, RE RN: In vitro evidence for an intracellular site of angiotensin action. Circ Res 89:1138-1146, 2001
18. NUNEZ A, GOMEZ J, ZALBA LR, et al: Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 1:175-179, 2000
19. CHENG SM, YANG SP, HO LJ, et al: Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1. Br J Pharmacol 142:933-942, 2004